Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Assetmark Inc.

Assetmark Inc. raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 18.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 102,436 shares of the biopharmaceutical company’s stock after buying an additional 16,299 shares during the quarter. Assetmark Inc. owned about 0.08% of Catalyst Pharmaceuticals worth $2,536,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. WINTON GROUP Ltd increased its position in shares of Catalyst Pharmaceuticals by 546.7% during the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock valued at $8,251,000 after purchasing an additional 298,862 shares during the period. Merit Financial Group LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $654,000. Wakefield Asset Management LLLP bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at $1,203,000. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Catalyst Pharmaceuticals by 30.0% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 167,763 shares of the biopharmaceutical company’s stock valued at $3,913,000 after buying an additional 38,695 shares during the period. Finally, Stratos Wealth Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 21.2% during the 4th quarter. Stratos Wealth Advisors LLC now owns 117,721 shares of the biopharmaceutical company’s stock worth $2,748,000 after acquiring an additional 20,628 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.49 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The stock has a market capitalization of $3.86 billion, a PE ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. The stock’s fifty day moving average is $31.38 and its 200-day moving average is $27.27.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CPRX shares. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. HC Wainwright lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Finally, Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).